Literature DB >> 3995684

The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80.

M N Azmin, J F Stuart, A T Florence.   

Abstract

This paper describes further exploration of the effect of polysorbate 80 on the absorption, distribution, and elimination of methotrexate (MTX). This study has confirmed the earlier finding that polysorbate 80 could increase the absorption of MTX from the mouse gastrointestinal tract and enhance the drugs uptake into the brain. The experiments reported here suggest that polysorbate 80 has a direct effect on the blood-brain barrier leading to the increased uptake of MTX, which is evident following IV administration. Measurements of MTX excreted in the urine and faeces confirmed the role of polysorbate 80 in facilitating the excretion of MTX into the bile and urine. Polysorbate 80 administered PO did not cause any reduction of plasma volume, thus excluding the possibility that the higher MTX concentrations measured in mice after concurrent administration of polysorbate PO might result from a reduction in blood volume due to osmotic effects. At the doses given, polysorbate 80 appeared not to have a damaging effect on the gastrointestinal mucosa.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995684     DOI: 10.1007/bf00258124

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Mechanism of drug absorption from micellar solution. II. Effect of polysorbate 80 on the absorption of micelle-free drugs.

Authors:  A Kaneda; K Nishimura; S Muranishi; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1974-03       Impact factor: 1.645

2.  Renal toxicity of methotrexate.

Authors:  P T Condit; R E Chanes; W Joel
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

3.  High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.

Authors:  G Rosen; F Ghavimi; A Nirenberg; C Mosende; B M Mehta
Journal:  Cancer Treat Rep       Date:  1977-07

4.  Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume.

Authors:  S D Harrison; A M Cusic; S M McAfee
Journal:  Eur J Cancer       Date:  1981-04       Impact factor: 9.162

5.  Absorption and excretion of drugs. XXVII. Effect of nonionic surface- active agents on rectal absorption of sulfonamides.

Authors:  K Kakemi; T Arita; S Muranishi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1965-08       Impact factor: 1.645

6.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

7.  Treatment of central nervous system tumors with methotrexate.

Authors:  H T Abelson; D W Kufe; A T Skarin; P Major; W Ensminger; G P Beardsley; G P Canellos
Journal:  Cancer Treat Rep       Date:  1981

8.  Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice.

Authors:  M N Azmin; J F Stuart; K C Calman; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Heuristic modeling of drug delivery to malignant brain tumors.

Authors:  V A Levin; C S Patlak; H D Landahl
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

10.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

View more
  11 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

Review 3.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 4.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.

Authors:  J C Olivier; L Fenart; R Chauvet; C Pariat; R Cecchelli; W Couet
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

6.  Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.

Authors:  R N Alyautdin; V E Petrov; K Langer; A Berthold; D A Kharkevich; J Kreuter
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

7.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.

Authors:  J Cummings; G J Forrest; D Cunningham; N L Gilchrist; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.

Authors:  I R Judson; C J Rutty; G Abel; M A Graham
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

Review 10.  Safety of Polysorbate 80 in the Oncology Setting.

Authors:  Lee S Schwartzberg; Rudolph M Navari
Journal:  Adv Ther       Date:  2018-05-23       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.